EE395 REAL-WORLD COST-EFFECTIVENESS AND OPPORTUNITY COSTS OF ANTI-IL-17/23 VERSUS ANTI-TNF? THERAPIES FOR PSORIASIS USING DLQI
Value in Health · 2026-06 · 29 (6) · S138
DOI: 10.1016/j.jval.2026.03.689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Rafael Gama und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gama, R., Heberle, P., Menoncin, S. M., Maciel, A. C., Toigo, D., Bueno, R., Utida, N., Medeiros, A. C. D., & Kroger, A. (2026). EE395 REAL-WORLD COST-EFFECTIVENESS AND OPPORTUNITY COSTS OF ANTI-IL-17/23 VERSUS ANTI-TNF? THERAPIES FOR PSORIASIS USING DLQI. Value in Health, 29(6), S138. https://doi.org/10.1016/j.jval.2026.03.689
Vancouver
Gama R, Heberle P, Menoncin SM, Maciel AC, Toigo D, Bueno R, et al. EE395 REAL-WORLD COST-EFFECTIVENESS AND OPPORTUNITY COSTS OF ANTI-IL-17/23 VERSUS ANTI-TNF? THERAPIES FOR PSORIASIS USING DLQI. Value in Health. 2026;29(6):S138. doi:10.1016/j.jval.2026.03.689
BibTeX
@article{Gama2026,
author = {Gama, Rafael and Heberle, Paula and Menoncin, Sergio M. and Maciel, Ana C. and Toigo, Daniela and Bueno, Ricardo and Utida, Nanci and Medeiros, Ana Cláudia de and Kroger, Aline},
title = {EE395 REAL-WORLD COST-EFFECTIVENESS AND OPPORTUNITY COSTS OF ANTI-IL-17/23 VERSUS ANTI-TNF? THERAPIES FOR PSORIASIS USING DLQI},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S138},
doi = {10.1016/j.jval.2026.03.689}
}
EUVIMED